Overview: The GLP-1 Question Reaches Migraine

Semaglutide, sold as Wegovy for weight management and Ozempic for type 2 diabetes, belongs to a class of drugs called GLP-1 receptor agonists. These medications have dominated headlines for weight loss and cardiovascular benefits, and researchers have started asking whether their effects extend to other conditions, including migraine.

There are reasons to take the question seriously. A small 2025 pilot study found that liraglutide, an older GLP-1 drug, reduced headache days in people with obesity and hard-to-treat migraine, and the improvement did not track with how much weight people lost. Preclinical work suggests GLP-1 receptor activation may influence migraine biology directly, possibly through effects on intracranial pressure and CGRP signaling.

Now a nationwide Danish study published in The Journal of Headache and Pain has taken a different approach: instead of running a small trial, the researchers watched what happened to triptan use across an entire country after 189,392 adults started weight-loss semaglutide. Triptans are acute migraine medications, so how often people fill triptan prescriptions serves as a rough real-world signal of migraine attack burden.

How the Study Worked

The researchers used Denmark's national pharmacy registers, which capture every prescription dispensed in the country. They identified all adults who started the weight-management formulation of semaglutide between December 2022 and December 2024, then tracked each person's triptan fills for 24 months before starting semaglutide and 12 months after.

Triptan use was measured in defined daily doses (DDD) per 10,000 individuals per month, a standard way to quantify medication consumption across a population. The team ran several checks on their findings, including a negative control (antibiotic eye drops, which should have no relationship to semaglutide and indeed showed none) and an alternative statistical approach (difference-in-differences), which pointed in the same direction.

Of the 189,392 people who started semaglutide, 68% were women and the median age was 50. About 4.5% had filled a triptan prescription in the prior year, and 9.7% had used a preventive migraine medication in the prior two years.

What They Found

The pattern matters as much as the numbers. Semaglutide initiation was not followed by an immediate drop in triptan use. Instead, a rising trend flipped to a declining one, and the gap widened month by month. That gradual slope change is more consistent with a slowly accruing biological or behavioral effect than with a sudden shift in prescribing.

Two other details are worth highlighting. First, the decline came almost entirely from people who were already using triptans taking less of them, not from fewer people starting triptans. In fact, the monthly rate of first-ever triptan users ticked up slightly (about 20 extra new users at 12 months across the whole cohort), a small absolute number that argues against semaglutide preventing migraine onset in people who never had it. Second, an extended analysis found the reduction was sustained at 24 months (RR 0.89, 95% CI 0.84 to 0.95).

Who Saw the Biggest Changes

The sex difference is intriguing but should be interpreted carefully. Women in the cohort used far more triptans at baseline than men (migraine is roughly three times more common in women), so the male analysis had less statistical power. Greater average weight loss with semaglutide in women, hormonal interactions, and differences in migraine biology are all plausible contributors, but none is established.

The authors flagged all subgroup findings as exploratory and hypothesis-generating. They were not adjusted for multiple comparisons.

Why Might GLP-1 Drugs Affect Migraine?

Several mechanisms could plausibly link GLP-1 receptor agonists to reduced migraine burden, and they are not mutually exclusive.

• Weight loss and metabolic effects. Obesity is associated with higher migraine frequency, and weight loss may reduce attack burden partly through inflammatory pathways.
• Intracranial pressure. GLP-1 drugs lower cerebrospinal fluid secretion and intracranial pressure, and some researchers hypothesize that subtle pressure dysregulation contributes to migraine in a subset of patients.
• Direct neural effects. In preclinical models, GLP-1 receptor activation reduced migraine-associated allodynia and the expression of migraine biomarkers, including CGRP, suggesting possible weight-independent central mechanisms.

The liraglutide pilot study is the most direct human evidence for a weight-independent effect: participants' headache days dropped from roughly 20 to 11 per month over 12 weeks while their BMI barely moved, and weight change did not predict headache improvement. That was a small, open-label study without a placebo group, so it is far from definitive, but it fits the pattern seen in the Danish data, where reductions appeared gradually and concentrated in people with established migraine.

Important Caveats

This is a well-designed observational study, but it has real limitations that the authors acknowledge directly.

• Triptan fills are a proxy, not a diagnosis. The study measured medication dispensing, not migraine attacks, headache days, or pain severity. People can fill fewer prescriptions for many reasons.
• No clinical data. The registers do not include body mass index, migraine subtype (with or without aura), or attack frequency, so the study cannot connect the reduction to weight loss or any specific migraine phenotype.
• Residual confounding. Starting a weight-loss drug often comes with broader lifestyle changes (diet, exercise, sleep, alcohol) that can themselves influence migraine. The negative control helps, but cannot exclude this.
• Industry involvement. The study was sponsored by Novo Nordisk, the manufacturer of semaglutide, and company employees are co-authors. The academic investigators retained control of the data and the decision to publish, and the protocol was preregistered, but the sponsorship is worth knowing when weighing the findings.
• Generalizability. Denmark has universal healthcare and specific prescribing patterns. Results may differ elsewhere.
• Modest effect size. A 7% relative reduction at the population level is meaningful scientifically but does not imply a dramatic clinical effect for any individual.

Key Takeaways

If you have migraine and are already taking or considering semaglutide for weight management or diabetes, this study is quietly encouraging: it suggests the drug is unlikely to worsen migraine at a population level and may modestly reduce the need for acute medication in some people. If you are wondering whether to pursue a GLP-1 drug specifically for migraine, the honest answer is that the evidence is not there yet. Talk with your healthcare provider about proven preventive options, and watch this space. Dedicated randomized trials of GLP-1 drugs in migraine are the logical next step, and this study strengthens the case for running them.